Effect of Eloizumab Injection on TIMI Flow Grade,Inflammatory Factors and Prognosis in Patients with Acute Coronary Syndrome after PCI
Objective To investigate the effect of eloizumab injection on thrombolysis in myocardial infarction(TI-MI)blood flow grading immediately after percutaneous coronary intervention(PCI),inflammatory factors and prognosis in pa-tients with acute coronary syndrome(ACS).Methods 120 patients with ACS who underwent emergency PCI in our hospital from January 2022 to December 2023 were selected.They were divided into control group(n=60)and study group(n=60).The control group was treated with rosuvastatin,and the study group was treated with evolocumab injection combined with rosuvastatin.TIMI blood flow classification and inflammatory indexes were compared between the two groups before and after treatment,and major adverse cardiovascular events(MACE)were recorded during 6 months of follow-up.Results Com-pared with before PCI,the TIMI blood flow grade increased immediately after PCI in the two groups(P＜0.05),while there was no significant difference in TIMI blood flow grade between the two groups immediately after operation(P＞0.05).Two months after PCI,the serum inflammatory markers of the two groups were lower than those before operation,and the study group was lower than the control group(P＜0.05).There was no significant difference in the incidence of MACE between the two groups within 6 months after PCI(P＞0.05).Conclusion The application of eloizumab injection in the treatment of ACS after emergency PCI can improve the distal vascular blood supply of the lesion,inhibit the inflammatory reaction,and do not increase the incidence of MACE.
国家科技期刊平台
NSTL
万方数据
